144 ·Filed May 14, 2026

RPRX

Royalty Pharma plc
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago SEC0001964306-26-000240
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine insider sale of a small number of shares acquired through equity compensation. No material signal for the stock. Monitor for any larger insider sales or changes in insider sentiment in future filings.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
RPRX ▲ +9.35% at T+60d
NEUTRAL call ✓ call won +9.35% · α vs SPY +4.83% · entry $52.85 → $57.79
Entry anchored
May 14, 03:59 PM ET
via exchange tick
T+1d
-1.48%
call -1.48% · α -1.41%
$52.07
settled 5mo ago
T+5d
+3.12%
call +3.12% · α +2.16%
$54.50
settled 4mo ago
T+20d
+2.69%
call +2.69% · α +0.57%
$54.27
settled 4mo ago
T+60d
+9.35%
call +9.35% · α +4.83%
$57.79
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Gregory Norden, an officer of Royalty Pharma, filed a Form 144 on May 14, 2026, indicating intent to sell 3,045 shares of common stock with an approximate market value of $161,385. The shares were acquired via vesting of restricted stock units on May 13, 2026, and the sale is a routine, small-dollar transaction relative to the company's $30.7B market cap.

Key Facts

  • Filer: Gregory Norden (officer of Royalty Pharma)
  • Proposed sale: 3,045 shares of common stock
  • Approximate value: $161,385 (based on filing date price)
  • Shares acquired via RSU vesting on May 13, 2026
  • Sale intended to be executed through Merrill Lynch
  • Transaction size is ~0.0005% of Royalty Pharma's $30.7B market cap

Financial Impact

Proceeds of approximately $161,385, representing a negligible fraction of market cap

dilution

Risk Factors

  • Insider selling could be perceived negatively if it precedes a negative catalyst, but the small size here makes that unlikely

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (16 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001964306-26-000240
Document: 0001964306-26-000240-index.html0001964306-26-000240
Document: 0001964306-26-000240.txt0001964306-26-000240
18 reports for RPRX
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+60▲ +15.20%May 6, 2026
Filters
Rows
Reports for RPRX — sortable, filterable
TypeNow
Sep 4, 2026
27d ago
Press Release
BEARISH ★ 5/10
$60.59 $58.47▲ +3.50%▲ +2.38%$57.16 (+5.66%)
Aug 19, 2026
6w ago
Insider Cluster
NEUTRAL ★ 3/10
$61.73 $61.80▲ +0.11%▲ +0.50%$57.16 (−7.40%)
Aug 12, 2026
7w ago
144
NEUTRAL ★ 3/10
$58.56 $60.58▲ +3.45%▲ +5.41%$57.16 (−2.39%)
Aug 5, 2026
8w ago
8-K
BULLISH ★ 6/10
$57.75 $59.22▲ +2.55%▲ +2.19%$57.16 (−1.02%)
Jul 2, 2026
13w ago
Insider Cluster
NEUTRAL ★ 2/10
$57.77 $57.96▲ +0.33%▼ −0.60%$57.16 (−1.06%)
Jul 2, 2026
13w ago
Insider Cluster
NEUTRAL ★ 2/10
$57.77 $57.96▲ +0.33%▼ −0.60%$57.16 (−1.06%)
May 28, 2026
18w ago
Insider Cluster
NEUTRAL ★ 4/10
$55.76 $55.87▲ +0.20%▲ +2.72%$57.16 (+2.51%)
May 28, 2026
18w ago
8-K
NEUTRAL ★ 4/10
$55.76 $54.97▼ −1.42%▼ −1.12%$57.16 (+2.51%)
May 22, 2026
19w ago
Insider Cluster
NEUTRAL ★ 2/10
$54.50 $55.18▲ +1.25%▼ −0.41%$57.16 (+4.88%)
May 15, 2026
19w ago
Insider Cluster
NEUTRAL ★ 3/10
$52.07 $53.86▲ +3.44%▲ +1.82%$57.16 (+9.78%)
Showing 10 of 18

US Market Status

Market Closed — Opens Mon (65h 6m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access